Cara Rabik



Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Cara Rabik is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Knock-In of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice

Annesley, C. E., Rabik, C., Duffield, A. S., Rau, R. E., Magoon, D., Li, L., Huff, V., Small, D., Loeb, D. M. & Brown, P. A., Oct 1 2018, In : Oncotarget. 9, 82, p. 35313-35326 14 p.

Research output: Contribution to journalArticle

  • Platinum pathway

    Marsh, S., McLeod, H., Dolan, E., Shukla, S. J., Rabik, C. A., Gong, L., Hernandez-Boussard, T., Lou, X. J., Klein, T. E. & Altman, R. B., Jul 1 2009, In : Pharmacogenetics and Genomics. 19, 7, p. 563-564 2 p.

    Research output: Contribution to journalShort survey

    Role of copper transporters in resistance to platinating agents

    Rabik, C. A., Maryon, E. B., Kasza, K., Shafer, J. T., Bartnik, C. M. & Dolan, M. E., Jun 1 2009, In : Cancer Chemotherapy and Pharmacology. 64, 1, p. 133-142 10 p.

    Research output: Contribution to journalArticle

  • Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress

    Rabik, C. A., Fishel, M. L., Holleran, J. L., Kasza, K., Kelley, M. R., Egorin, M. J. & Dolan, M. E., Nov 1 2008, In : Journal of Pharmacology and Experimental Therapeutics. 327, 2, p. 442-452 11 p.

    Research output: Contribution to journalArticle